Search

Your search keyword '"Jaffrani N"' showing total 32 results

Search Constraints

Start Over You searched for: Author "Jaffrani N" Remove constraint Author: "Jaffrani N"
32 results on '"Jaffrani N"'

Search Results

1. Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation

2. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

3. Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice:: GLORIA-AF Registry

4. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

5. Dapagliflozin and cardiovascular outcomes in type 2 diabetes

6. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

7. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

8. Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry

9. Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)

10. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

11. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness

12. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness

13. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

14. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery

15. Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

16. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial

17. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

18. Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure

19. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

20. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

21. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF

22. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

23. Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

25. Alogliptin after acute coronary syndrome in patients with type 2 diabetes

26. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

27. Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation. the GLORIA-AF registry

28. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

29. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

30. An "Inclisiran First" Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease.

31. Efficacy and safety of MAS825 (anti-IL-1β/IL-18) in COVID-19 patients with pneumonia and impaired respiratory function.

Catalog

Books, media, physical & digital resources